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Objectives: The aim of this study was to evaluate 
BKV quantitation i urine and plasma samples with 
real-time PCR in renal transplant recipients for 
diagnosing BKV associated nephropathy. 
Methods: We performed PCR assays for BKV DNA 
in plasma and urine samples from three renal a[- 
[ograft recipients with suspected BKV associated 
nephropaty. DNA was extracted with the QIAamp 
blood minikit (Qiagen) from samples. Quantitative 
real-time PCR assays were performed using the 
Rotor-Gene instrument (Corbett Research, Sydney, 
Australia). Standart curves for the quantification 
of BKV were constructed using serial dilutions of 
a p[asmid containing the entire [inearized genome 
of the BK virus Dunlop strain inserted into the Barn 
H1 restriction site of the pBR322 p[asmid (ATCC 
45025). PCR primers for the BKV VP1 gene and 
dual labeled probe at the 5' end with 6-carboxy- 
fluorescein (FAM) and the 3' end with 6-carboxy- 
tetramethy[rhodamine (TAMPA) were used for the 
amplification reactions. To ensure that negative 
results were not due to nonspecific inhibition of 
the PCR, each PCR reaction was spiked with a 
p[asmid containing [ycose 6 phosphate dehydro- 
genase gene and specific primers and dual labeled 
probe at the 5' end with BHQ3 and the 3' end 
with TAMPA were used. Urine samples were also 
analyzed for the presence of BKV inclusion bearing 
Decoy ceils after centrifugation and Papanico[au 
staining. Histopatho[ogica[ examination of a[[ograft 
biopsies were performed for two patients. 
Results: Decoy ceils were found in a[[ urine sam- 
pies analysed. For urine and plasma samples from 
two patients, BKV DNA levels were above sug- 
gested thresholds (10,000,000copies/m[ for urine 
and 10,000copies/m[ for plasma) related with 
BKV associated nephropathy. Histopatho[ogica[ ex- 
amination of a[[ograft biopsies from these pa- 
tients confirmed the presence of BKV associated 
nephropathy. For the other renal a[[ograft recipient 
BKV DNA levels in both plasma and urine samples 
were below thresholds 
Conclusions: Detection of BKV DNA in plasma and 
urine samples by real-time PCR is a rapid and 
easy method and a useful[ too[ for determining the 
course of BKV infections. 
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Background: Invasive funga[ infections (IFI) cause 
considerable mortality in immunocompromised pa- 
tients. Recent developments of antifunga[ drugs 
have significantly improved outcomes, particularly 
regarding Candida and Aspersillus spp. However, 
mucormycosis are not we[[ covered by currently 
licensed drugs. 
Objectives: We report a heart transplant (HTx) 
patient who developed bilateral pulmonary lesions 
4 months after transplantation and 3 weeks after a 
successfully treated relapse of a 1 ° CMV infection 
following donor-recipient mismatch (D+/R-). 
Methods E Results: 4 months after HTx and one re- 
jection episode (ISHLT II) treated with oral steroids; 
a 52 year old male patient was admitted with acute 
thoracic pain and cough. 3 weeks earlier a recur- 
rent 1 ° CMV primary infection had been treated 
preemptive with gancic[ovir i.v. followed by oral 
va[gancic[ovir. Clinical examination revealed slight 
deterioration of genera[ condition, dry cough, 
dyspnea, no fever (leukocyte count 9.6×109/L, 
>90% neutrophi[s, C-reactive protein 201 mg/L). 
Empiric antibiotic treatment with [evofloxacin was 
started after specimens were taken for micro- 
biology studies. CT-scan revealed extensive [eft- 
sided pleura[ effusion and suspicion of pneumonia 
and abscess in the [eft lower lobe. Pleura[ effu- 
sion was drained (pH 7.37, glucose 5.8mmo[/L), 
but no etiology was identified. CT-scans 5 days 
later revealed increasing pulmonary abscess for- 
mation [eft and new lesions right. Needle biopsy 
and culture revealed Clostridium spp and Rhizopus 
spp. Levofloxacin was replaced with i.v. imipenem, 
amikacin, and antimycotic therapy was started 
consisting of oral terbinafin and [ipophi[ic ampho- 
tericin B i.v. In a 2 step procedure, lung lesions 
were resected from lower [eft ([obectomy), and 
after one week, atypically from the right lower 
lobe. Invasive mucormycosis was detected in a[[ 
specimens microbio[ogica[[y and histologically. An- 
tifunga[ regimen was changed to oral posacona- 
zo[e (400 mg p.o bid). Resistance testing revealed 
MIC 1 ug/mL. Further course was uneventful and 
the patient was discharged after 3 weeks for fur- 
ther rehabilitation. At 2 years post-diagnosis, the 
patient is fine without documented recurrence of 
funga[ lesions and posaconazo[e is tolerated we[[. 
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Conclusion: Combined approach of surgica[ re- 
section and the use of the investigationa[ drug 
posaconazote was key to successfutty treat the 
highty [etha[ invasive putmonary mucormycosis n
a heart transptant patient requiring continuous im- 
munosuppression. 
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Introduction E Background: Infections represent 
a significant hreat in sotid-organ recipients. How- 
ever, a certain number of infections can be pre- 
vented by immunizing patients before their trans- 
ptantation. The aim of this study is to determine 
the immunization revers of chitdren undergoing 
transptantation and to assess their capacity to 
maintain protective revers after surgery. 
Methods: Charts of 44 chitdren transptanted with 
cadaveric rivers between 1990 and 2002 at the 
Chitdren's Hospita[ of Geneva were reviewed. Vac- 
cination types and schedutes were compared to 
current recommendations and antibody responses 
to certain antigens were estabtished pre- and post- 
transptantation. 
Results: Onty 43% of patients were up to date for 
diphtheria, tetanus, acettutar pertussis, and potio 
vaccines at the pre-transptant visit, white 44% of 
chitdren order than 12 months had received their 
required meastes-mumps-rubetta shots. Six out of 
44 chitdren had received at [east one dose of hep- 
atitis B vaccine, white onty 2 patients had received 
at [east one dose of hepatitis A vaccine. After 
immunization, and one year after transptantation, 
onty 14/44 patients had detectabte anti-HBs anti- 
bodies and 7/18 had anti-HAV antibodies. Varicetta 
antibodies were undetectabte in 15/19 patients 
immunized prior to transptantation. 
Conclusions: This study hightights the need to en- 
force vaccination before transptantation, fottow- 
up on vaccine-induced immunity, and adapt vac- 
cination schedutes after river transptantation i
chitdren, especiatty for non-tire vaccines which are 
universatty recommended in this poputation. 
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Background E Methods: Respiratory syncytial 
virus (RSV) infections in tung transptant pa- 
tients (LTP) have been associated with mortat- 
ity rates between 10% and 70%. Immunogtobu- 
tines (IG), ribavirine and pavitizumab have been 
suggested for both therapeutic and pre-emptive 
therapeutic approaches, however they are [imited 
by toxicity concerns and high costs. In order to 
design a decisiona[ treatment ree we describe 
four cases of proven tower respiratory tract RSV 
infections in tung transptant patients ittustrating 
possibte different ctinica[ approaches. 
Results: Case 1: A 54-year-otd femate LTP was 
hospitatized with cough, bronchitis and rhinorrhea. 
The bronchoatveotar r vage (BAL) grew 105 CFU/m[ 
of S. aureus and S. marcescens suggesting a bacte- 
ria[ pneumonia responding wet[ to cefepime and a 
transient reduction in immunosuppression. Subse- 
quentty a positive PER resutt for RSV was obtained 
from the same BAL. She evotved favourabty with- 
out a therapy against RSV. Case 2: A 28-year-otd 
mate LTP was hospitatized for fever and "common 
cord'. Putmonary functions were ctearty worsened 
compared to two weeks before. The BAL resutts 
suggested a vira[ infection that was treated by a 
reduction in immunosuppression. After one week 
the putmonary functions and ctinica[ symptoms had 
improved. A positive PER for RSV was obtained 
from the origina[ BAL. A specific treatment against 
RSV was not necessary. Case 3: A 48-year-otd fe- 
mate LTP was hospitatized for rhinitis, cough and 
increased sputum production. A tung biopsy re- 
reared an acute A3 rejection. The BAL yietded a 
positive vira[ cutture and PER for RSV. IG associated 
with ribavirine and pavitizumab were administered 
before the treatment of the rejection by anti- 
thymogtobutines. He evotved favourabty without 
significant side effect of the anti-RSV treatment. 
Case 4: A 62-year-otd tung transptant patient was 
hospitatized for rhinorrhea, fever, myatgia, cough, 
severe wheezing and ground grass opacities in the 
middte robe. Withdrawa[ of mycophenotate was 
fottowed by a significant spirometric and ctinica[ 
improvement. Secondarity the BAL yietded a pos- 
itive PER resutt for RSV. He evotved favourabty 
without specific anti-RSV treatment. 
